CONCLUSIONS	O
:	O
The	O
combination	O
of	O
paclitaxel	B-Chemical
,	O
cisplatin	B-Chemical
,	O
and	O
gemcitabine	B-Chemical
is	O
well	O
tolerated	O
and	O
shows	O
high	O
activity	O
in	O
metastatic	O
NSCLC	B-Disease
.	O

Therefore	O
,	O
patients	O
with	O
glioblastoma	B-Disease
sometimes	O
have	O
intracarotid	O
injection	O
of	O
carcinostatics	O
added	O
to	O
the	O
treatment	O
regimen	O
.	O

These	O
results	O
suggest	O
that	O
the	O
facilitation	O
of	O
memory	O
retrieval	O
by	O
pre	O
-	O
test	O
morphine	B-Chemical
might	O
be	O
the	O
direct	O
action	O
of	O
morphine	B-Chemical
rather	O
than	O
a	O
state	O
dependent	O
effect	O
.	O

In	O
behavioral	O
studies	O
,	O
pre	O
-	O
treatment	O
of	O
mice	O
with	O
BD1018	B-Chemical
,	O
BD1063	B-Chemical
,	O
or	O
LR132	B-Chemical
significantly	O
attenuated	O
cocaine	B-Chemical
-	O
induced	O
convulsions	B-Disease
and	O
lethality	O
.	O

Twenty	O
-	O
three	O
h	O
postoperatively	O
he	O
developed	O
a	O
brief	O
self	O
-	O
limited	O
seizure	B-Disease
.	O

Moderate	O
abnormalities	O
require	O
a	O
reduction	O
of	O
deferoxamine	B-Chemical
to	O
25	O
mg	O
/	O
kg	O
per	O
dose	O
with	O
careful	O
monitoring	O
.	O

Following	O
instrumentation	O
,	O
halothane	B-Chemical
was	O
discontinued	O
and	O
alfentanil	B-Chemical
(	O
125	O
mu	O
/	O
kg	O
)	O
administered	O
iv	O
during	O
emergence	O
from	O
halothane	B-Chemical
anesthesia	O
.	O

To	O
this	O
end	O
,	O
doxorubicin	B-Chemical
(	O
15	O
mug	O
/	O
g	O
body	O
wt	O
)	O
was	O
injected	O
intravenously	O
into	O
gene	O
-	O
targeted	O
mice	O
lacking	O
SGK1	O
(	O
sgk1	O
(	O
-	O
/	O
-	O
)	O
)	O
and	O
their	O
wild	O
-	O
type	O
littermates	O
(	O
sgk1	O
(	O
+	O
/	O
+	O
)	O
)	O
.	O

Many	O
patients	O
,	O
however	O
,	O
develop	O
negative	O
long	O
-	O
term	O
side	O
effects	O
such	O
as	O
premature	B-Disease
atherosclerosis	I-Disease
.	O

PD	O
female	O
rats	O
also	O
showed	O
increased	O
(	O
3	O
)	O
H	B-Chemical
-	O
haloperidol	B-Chemical
binding	O
and	O
decreased	O
dopamine	B-Chemical
transporter	O
binding	O
in	O
striatum	O
.	O

Cardiomyopathy	B-Disease
is	O
frequent	O
when	O
the	O
total	O
dose	O
exceeds	O
600	O
mg	O
/	O
m2	O
and	O
occurs	O
within	O
one	O
to	O
six	O
months	O
after	O
cessation	O
of	O
therapy	O
.	O

An	O
experiment	O
was	O
performed	O
to	O
test	O
whether	O
inclusion	O
of	O
phenobarbital	B-Chemical
in	O
a	O
choline	B-Chemical
-	O
devoid	O
diet	O
would	O
increase	O
the	O
hepatocarcinogenicity	O
of	O
the	O
diet	O
.	O

Adverse	O
reactions	O
possibly	O
attributable	O
to	O
didanosine	B-Chemical
were	O
common	O
.	O

Thirty	O
-	O
six	O
patients	O
were	O
treated	O
with	O
BCNU	B-Chemical
every	O
6	O
to	O
8	O
weeks	O
,	O
either	O
by	O
transfemoral	O
catheterization	O
of	O
the	O
internal	O
carotid	O
or	O
vertebral	O
artery	O
or	O
through	O
a	O
fully	O
implantable	O
intracarotid	O
drug	O
delivery	O
system	O
,	O
beginning	O
with	O
a	O
dose	O
of	O
200	O
mg	O
/	O
sq	O
m	O
body	O
surface	O
area	O
.	O

Treatment	O
-	O
related	O
adverse	O
events	O
(	O
AEs	O
)	O
occurred	O
in	O
44	O
%	O
and	O
52	O
%	O
,	O
57	O
%	O
,	O
and	O
41	O
%	O
of	O
the	O
asenapine	B-Chemical
at	O
5	O
and	O
10	O
mg	O
BID	O
,	O
haloperidol	B-Chemical
,	O
and	O
placebo	O
groups	O
,	O
respectively	O
.	O

Normalizing	O
effects	O
of	O
modafinil	B-Chemical
on	O
sleep	O
in	O
chronic	O
cocaine	B-Chemical
users	O
.	O

Inappropriate	O
use	O
of	O
carbamazepine	B-Chemical
and	O
vigabatrin	B-Chemical
in	O
typical	O
absence	B-Disease
seizures	I-Disease
.	O

Pregnant	O
rats	O
were	O
given	O
either	O
vehicle	O
or	O
2	O
daily	O
intraperitoneal	O
injections	O
of	O
dexamethasone	B-Chemical
(	O
0	O
.	O
2	O
mg	O
/	O
kg	O
body	O
weight	O
)	O
on	O
gestational	O
days	O
11	O
and	O
12	O
,	O
13	O
and	O
14	O
,	O
15	O
and	O
16	O
,	O
17	O
and	O
18	O
,	O
or	O
19	O
and	O
20	O
.	O

The	O
pharmacological	O
challenge	O
data	O
suggest	O
that	O
tolerance	O
may	O
occur	O
to	O
seizure	B-Disease
activity	O
induced	O
by	O
PTZ	B-Chemical
and	O
PTX	B-Chemical
24	O
h	O
after	O
gamma	B-Chemical
-	I-Chemical
HCH	I-Chemical
,	O
since	O
the	O
response	O
to	O
only	O
these	O
two	O
seizure	B-Disease
-	O
inducing	O
agents	O
is	O
decreased	O
.	O

International	O
mexiletine	B-Chemical
and	O
placebo	O
antiarrhythmic	O
coronary	O
trial	O
:	O
I	O
.	O

However	O
,	O
compression	B-Disease
neuropathy	I-Disease
due	O
to	O
fibrotic	O
muscle	O
affected	O
by	O
pentazocine	B-Chemical
-	O
induced	O
myopathy	B-Disease
has	O
not	O
previously	O
been	O
reported	O
.	O

These	O
results	O
indicate	O
a	O
reliable	O
memory	O
for	O
magnitude	O
and	O
duration	O
of	O
experimentally	O
induced	O
pain	B-Disease
.	O

What	O
is	O
less	O
well	O
known	O
is	O
a	O
phenomenon	O
whereby	O
statins	B-Chemical
may	O
induce	O
a	O
myopathy	B-Disease
,	O
which	O
persists	O
or	O
may	O
progress	O
after	O
stopping	O
the	O
drug	O
.	O

Eight	O
of	O
the	O
isolated	O
-	O
HIT	B-Disease
patients	O
developed	O
thrombosis	B-Disease
within	O
the	O
next	O
30	O
d	O
;	O
thus	O
,	O
a	O
total	O
of	O
48	O
patients	O
had	O
thrombosis	B-Disease
at	O
day	O
30	O
.	O

Adriamycinol	B-Chemical
,	O
doxorubicin	B-Chemical
,	O
adriamycinone	B-Chemical
,	O
and	O
tetrahydropyranyladriamycinol	B-Chemical
were	O
the	O
metabolites	O
detected	O
in	O
plasma	O
and	O
the	O
amount	O
of	O
doxorubicin	B-Chemical
was	O
less	O
than	O
or	O
equal	O
to	O
10	O
%	O
of	O
the	O
total	O
metabolites	O
.	O

Treatment	O
for	O
2	O
weeks	O
with	O
Warfarin	B-Chemical
caused	O
massive	O
focal	O
calcification	B-Disease
of	I-Disease
the	I-Disease
artery	I-Disease
media	O
in	O
20	O
-	O
day	O
-	O
old	O
rats	O
and	O
less	O
extensive	O
focal	O
calcification	B-Disease
in	O
42	O
-	O
day	O
-	O
old	O
rats	O
.	O

Confusion	B-Disease
mostly	O
occurred	O
during	O
the	O
two	O
first	O
weeks	O
following	O
valproic	B-Chemical
acid	I-Chemical
exposure	O
(	O
39	O
.	O
7	O
%	O
)	O
.	O

Therefore	O
,	O
concomitant	O
administration	O
of	O
small	O
doses	O
of	O
bradykinin	B-Chemical
receptor	O
antagonists	O
and	O
NO	B-Chemical
synthase	O
inhibitors	O
can	O
be	O
effective	O
in	O
alleviation	O
of	O
neuropathic	B-Disease
pain	I-Disease
,	O
even	O
in	O
hospital	O
care	O
.	O

The	O
electrocardiograms	O
(	O
ECG	O
)	O
of	O
99	O
cocaine	B-Chemical
-	O
abusing	O
patients	O
were	O
compared	O
with	O
the	O
ECGs	O
of	O
50	O
schizophrenic	B-Disease
controls	O
.	O

RESULTS	O
:	O
We	O
report	O
seven	O
cases	O
where	O
substitution	O
of	O
lithium	B-Chemical
,	O
either	O
fully	O
or	O
partially	O
,	O
with	O
divalproex	B-Chemical
sodium	I-Chemical
was	O
extremely	O
helpful	O
in	O
reducing	O
the	O
cognitive	B-Disease
,	I-Disease
motivational	I-Disease
,	I-Disease
or	I-Disease
creative	I-Disease
deficits	I-Disease
attributed	O
to	O
lithium	B-Chemical
in	O
our	O
bipolar	B-Disease
patients	O
.	O

Anthracyclines	B-Chemical
are	O
effective	O
antineoplastic	O
drugs	O
,	O
but	O
they	O
frequently	O
cause	O
dose	O
-	O
related	O
cardiotoxicity	B-Disease
.	O

We	O
used	O
an	O
in	O
vitro	O
model	O
of	O
chemotherapy	O
induced	O
peripheral	B-Disease
neuropathy	I-Disease
that	O
closely	O
mimic	O
the	O
in	O
vivo	O
condition	O
by	O
exposing	O
primary	O
cultures	O
of	O
dorsal	O
root	O
ganglion	O
(	O
DRG	O
)	O
sensory	O
neurons	O
to	O
paclitaxel	B-Chemical
and	O
cisplatin	B-Chemical
,	O
two	O
widely	O
used	O
and	O
highly	O
effective	O
chemotherapeutic	O
drugs	O
.	O

Memory	O
retrieval	O
of	O
experiences	O
acquired	O
prior	O
to	O
cocaine	B-Chemical
administration	O
was	O
impaired	O
and	O
negatively	O
correlated	O
with	O
NFkappaB	O
activity	O
in	O
the	O
frontal	O
cortex	O
.	O

Proteinuria	B-Disease
was	O
measured	O
every	O
2	O
weeks	O
.	O

This	O
study	O
is	O
the	O
first	O
to	O
demonstrate	O
that	O
impairment	O
of	O
hepatocyte	O
TJs	O
occurs	O
heterogenously	O
in	O
the	O
liver	O
lobule	O
after	O
BDL	O
and	O
suggests	O
that	O
BDL	O
and	O
EE	B-Chemical
treatments	O
produce	O
different	O
lobular	O
distributions	O
of	O
increased	O
paracellular	O
permeability	O
.	O

As	O
no	O
other	O
medications	O
known	O
to	O
effect	O
serum	O
potassium	B-Chemical
had	O
been	O
given	O
concomitantly	O
,	O
this	O
course	O
of	O
events	O
is	O
suggestive	O
of	O
a	O
cause	O
-	O
and	O
-	O
effect	O
relationship	O
between	O
sulindac	B-Chemical
and	O
hyperkalemia	B-Disease
.	O

Differential	O
impact	O
of	O
immune	O
escape	O
mutations	O
G145R	O
and	O
P120T	O
on	O
the	O
replication	O
of	O
lamivudine	B-Chemical
-	O
resistant	O
hepatitis	B-Chemical
B	I-Chemical
virus	I-Chemical
e	I-Chemical
antigen	I-Chemical
-	O
positive	O
and	O
-	O
negative	O
strains	O
.	O

Myocardial	O
concentrations	O
of	O
calcium	B-Chemical
also	O
increased	O
significantly	O
(	O
12	O
.	O
0	O
vs	O
.	O
5	O
.	O
0	O
mg	O
.	O
per	O
100	O
Gm	O
.	O
of	O
fat	O
-	O
free	O
dry	O
weight	O
)	O
.	O

Because	O
of	O
the	O
need	O
for	O
the	O
development	O
of	O
new	O
treatments	O
for	O
Crohn	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
,	O
a	O
pilot	O
study	O
was	O
undertaken	O
to	O
estimate	O
the	O
pharmacodynamics	O
and	O
tolerability	O
of	O
fusidic	B-Chemical
acid	I-Chemical
treatment	O
in	O
chronic	O
active	O
,	O
therapy	O
-	O
resistant	O
patients	O
.	O

To	O
better	O
understand	O
the	O
utility	O
of	O
GLEPP1	O
as	O
a	O
marker	O
of	O
glomerular	B-Disease
injury	I-Disease
,	O
the	O
amount	O
and	O
distribution	O
of	O
GLEPP1	O
protein	O
and	O
mRNA	O
were	O
examined	O
by	O
immunohistochemistry	O
,	O
Western	O
blot	O
and	O
RNase	O
protection	O
assay	O
in	O
a	O
model	O
of	O
podocyte	O
injury	O
in	O
the	O
rat	O
.	O

In	O
Group	O
1	O
the	O
rats	O
were	O
trained	O
under	O
the	O
influence	O
of	O
pentobarbital	B-Chemical
to	O
run	O
to	O
the	O
same	O
shelf	O
as	O
in	O
the	O
normal	O
state	O
.	O

We	O
prospectively	O
evaluated	O
the	O
adverse	O
reactions	O
of	O
apraclonidine	B-Chemical
in	O
20	O
normal	O
volunteers	O
by	O
instilling	O
a	O
single	O
drop	O
of	O
1	O
%	O
apraclonidine	B-Chemical
in	O
their	O
right	O
eyes	O
.	O

Isoniazid	B-Chemical
was	O
the	O
most	O
frequent	O
agent	O
in	O
drug	O
-	O
induced	O
neuropathy	B-Disease
.	O

We	O
postulate	O
that	O
by	O
virtue	O
of	O
its	O
direct	O
blocking	O
action	O
on	O
IKr	O
,	O
ketoconazole	B-Chemical
alone	O
may	O
prolong	O
QT	O
interval	O
and	O
induce	O
TdP	B-Disease
.	O

OBJECTIVE	O
:	O
To	O
examine	O
the	O
safety	O
and	O
tolerability	O
of	O
clonidine	B-Chemical
used	O
alone	O
or	O
with	O
methylphenidate	B-Chemical
in	O
children	O
with	O
attention	B-Disease
-	I-Disease
deficit	I-Disease
/	I-Disease
hyperactivity	I-Disease
disorder	I-Disease
(	O
ADHD	B-Disease
)	O
.	O

The	O
aorta	O
/	O
serum	O
-	O
ratio	O
and	O
the	O
radioactive	O
build	O
-	O
up	O
24	O
and	O
48	O
hours	O
after	O
injection	O
of	O
131I	O
-	O
HSA	O
was	O
reduced	O
in	O
animals	O
treated	O
with	O
D	B-Chemical
-	I-Chemical
pen	I-Chemical
for	O
42	O
days	O
,	O
indicating	O
an	O
impeded	O
transmural	O
transport	O
of	O
tracer	O
which	O
may	O
be	O
caused	O
by	O
a	O
steric	O
exclusion	O
effect	O
of	O
abundant	O
hyaluronate	B-Chemical
.	O

CONCLUSION	O
:	O
eleven	O
of	O
13	O
patients	O
with	O
a	O
prolonged	O
duration	O
of	O
action	O
of	O
succinylcholine	B-Chemical
had	O
mutations	O
in	O
BCHE	O
,	O
indicating	O
that	O
this	O
is	O
the	O
possible	O
reason	O
for	O
a	O
prolonged	O
period	O
of	O
apnea	B-Disease
.	O

Given	O
alone	O
to	O
any	O
accumbal	O
subregion	O
,	O
GR	B-Chemical
55562	I-Chemical
(	O
0	O
.	O
1	O
-	O
10	O
microg	O
/	O
side	O
)	O
or	O
CP	B-Chemical
93129	I-Chemical
(	O
0	O
.	O
1	O
-	O
10	O
microg	O
/	O
side	O
)	O
did	O
not	O
change	O
basal	O
locomotor	O
activity	O
.	O

Combined	O
androgen	O
blockade	O
-	O
induced	O
anemia	B-Disease
in	O
prostate	B-Disease
cancer	I-Disease
patients	O
without	O
bone	O
involvement	O
.	O

Marital	O
unhappiness	O
,	O
as	O
indicated	O
by	O
AMHS	O
scores	O
,	O
was	O
not	O
associated	O
with	O
arthritis	B-Disease
but	O
was	O
associated	O
with	O
sexual	B-Disease
dysfunction	I-Disease
,	O
sexual	O
dissatisfaction	O
and	O
being	O
female	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
that	O
Rg1	B-Chemical
might	O
be	O
a	O
useful	O
agent	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
the	O
adverse	O
effects	O
of	O
morphine	B-Chemical
.	O

CONCLUSIONS	O
:	O
Results	O
of	O
these	O
studies	O
suggest	O
that	O
B1	O
and	O
B2	O
receptors	O
are	O
engaged	O
in	O
transmission	O
of	O
nociceptive	O
stimuli	O
in	O
both	O
diabetic	B-Disease
and	I-Disease
toxic	I-Disease
neuropathy	I-Disease
.	O

And	O
the	O
results	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
morphine	B-Chemical
acts	O
by	O
retarding	O
the	O
release	O
of	O
acetylcholine	B-Chemical
at	O
some	O
central	O
cholinergic	O
synapses	O
.	O

We	O
conclude	O
that	O
methylphenidate	B-Chemical
mediated	O
vasculitis	B-Disease
should	O
be	O
considered	O
in	O
patients	O
with	O
neurological	O
symptoms	O
and	O
a	O
history	O
of	O
methylphenidate	B-Chemical
therapy	O
.	O

Iatrogenically	O
induced	O
intractable	O
atrioventricular	B-Disease
reentrant	I-Disease
tachycardia	I-Disease
after	O
verapamil	B-Chemical
and	O
catheter	O
ablation	O
in	O
a	O
patient	O
with	O
Wolff	B-Disease
-	I-Disease
Parkinson	I-Disease
-	I-Disease
White	I-Disease
syndrome	I-Disease
and	O
idiopathic	B-Disease
dilated	I-Disease
cardiomyopathy	I-Disease
.	O

Previous	O
reports	O
have	O
suggested	O
that	O
pain	B-Disease
associated	O
with	O
the	O
injection	O
of	O
lidocaine	B-Chemical
is	O
related	O
to	O
the	O
acidic	O
pH	O
of	O
the	O
solution	O
.	O

Omitting	O
fentanyl	B-Chemical
reduces	O
nausea	B-Disease
and	O
vomiting	B-Disease
,	O
without	O
increasing	O
pain	B-Disease
,	O
after	O
sevoflurane	B-Chemical
for	O
day	O
surgery	O
.	O

Lamivudine	B-Chemical
therapy	O
was	O
started	O
3	O
-	O
7	O
days	O
prior	O
to	O
immunosuppressive	O
therapy	O
in	O
all	O
patients	O
.	O

Behavioral	O
effects	O
of	O
diazepam	B-Chemical
and	O
propranolol	B-Chemical
in	O
patients	O
with	O
panic	B-Disease
disorder	I-Disease
and	O
agoraphobia	B-Disease
.	O

Urinary	O
volume	O
and	O
serum	O
creatinine	B-Chemical
levels	O
recovered	O
to	O
the	O
normal	O
range	O
,	O
with	O
urinary	O
protein	O
disappearing	O
completely	O
within	O
40	O
days	O
.	O

RESULTS	O
:	O
The	O
main	O
pathologic	O
diagnoses	O
(	O
some	O
overlap	O
)	O
were	O
acute	O
rejection	O
(	O
AR	O
;	O
n	O
=	O
4	O
)	O
,	O
chronic	O
rejection	O
(	O
CR	O
;	O
n	O
=	O
5	O
)	O
,	O
AR	O
+	O
CR	O
(	O
n	O
=	O
4	O
)	O
,	O
recurrent	O
IgA	B-Disease
nephropathy	I-Disease
(	O
n	O
=	O
5	O
)	O
,	O
normal	O
findings	O
(	O
n	O
=	O
2	O
)	O
,	O
minimal	O
-	O
type	O
chronic	O
FK506	B-Chemical
nephropathy	B-Disease
(	O
n	O
=	O
9	O
)	O
,	O
and	O
mild	O
-	O
type	O
FK506	B-Chemical
nephropathy	B-Disease
(	O
n	O
=	O
11	O
)	O
.	O

The	O
rabbit	B-Disease
syndrome	I-Disease
is	O
an	O
extrapyramidal	O
side	O
effect	O
associated	O
with	O
chronic	O
neuroleptic	O
therapy	O
.	O

PURPOSE	O
:	O
We	O
reviewed	O
the	O
results	O
of	O
serum	O
testosterone	B-Chemical
and	O
prolactin	O
determination	O
in	O
1	O
,	O
022	O
patients	O
referred	O
because	O
of	O
erectile	B-Disease
dysfunction	I-Disease
and	O
compared	O
the	O
data	O
with	O
history	O
,	O
results	O
of	O
physical	O
examination	O
,	O
other	O
etiological	O
investigations	O
and	O
effects	O
of	O
endocrine	O
therapy	O
to	O
refine	O
the	O
rules	O
of	O
cost	O
-	O
effective	O
endocrine	O
screening	O
and	O
to	O
pinpoint	O
actual	O
responsibility	O
for	O
hormonal	O
abnormalities	O
.	O

Deep	O
forearm	O
venous	O
samples	O
were	O
collected	O
for	O
determination	O
of	O
L	B-Chemical
-	I-Chemical
arginine	I-Chemical
extraction	O
.	O

Diclofenac	B-Chemical
sodium	I-Chemical
(	O
Voltarol	B-Chemical
,	O
Geigy	O
Pharmaceuticals	O
)	O
is	O
a	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
derivative	O
of	O
phenylacetic	B-Chemical
acid	I-Chemical
.	O

STUDY	O
OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
frequency	O
of	O
venous	B-Disease
thromboembolism	I-Disease
(	O
VTE	B-Disease
)	O
in	O
patients	O
with	O
advanced	O
androgen	O
-	O
independent	O
prostate	B-Disease
cancer	I-Disease
who	O
were	O
treated	O
with	O
docetaxel	B-Chemical
alone	O
or	O
in	O
combination	O
with	O
thalidomide	B-Chemical
.	O

RESULTS	O
:	O
Testosterone	B-Chemical
was	O
less	O
than	O
3	O
ng	O
.	O
/	O
ml	O
.	O
in	O
107	O
patients	O
but	O
normal	O
in	O
40	O
%	O
at	O
repeat	O
determination	O
.	O

Acute	O
hepatitis	B-Disease
,	O
autoimmune	B-Disease
hemolytic	I-Disease
anemia	I-Disease
,	O
and	O
erythroblastocytopenia	B-Disease
induced	O
by	O
ceftriaxone	B-Chemical
.	O

Physicians	O
who	O
prescribe	O
molindone	B-Chemical
should	O
be	O
aware	O
of	O
this	O
reaction	O
.	O

These	O
preliminary	O
results	O
suggest	O
that	O
BNP	O
may	O
be	O
useful	O
as	O
an	O
early	O
and	O
sensitive	O
indicator	O
of	O
anthracycline	B-Chemical
-	O
induced	O
cardiotoxicity	B-Disease
.	O

BACKGROUND	O
:	O
Incidence	O
and	O
risk	O
factors	O
for	O
delirium	B-Disease
during	O
clozapine	B-Chemical
treatment	O
require	O
further	O
clarification	O
.	O

Both	O
,	O
Ro4368554	B-Chemical
(	O
3	O
and	O
10	O
mg	O
/	O
kg	O
,	O
intraperitoneally	O
(	O
i	O
.	O
p	O
.	O
)	O
)	O
and	O
metrifonate	B-Chemical
(	O
10	O
mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
,	O
respectively	O
)	O
reversed	O
memory	B-Disease
deficits	I-Disease
induced	O
by	O
scopolamine	B-Chemical
and	O
TRP	B-Chemical
depletion	O
(	O
10	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
,	O
and	O
3	O
mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
,	O
respectively	O
)	O
.	O

Here	O
we	O
show	O
that	O
perceived	O
pain	B-Disease
intensity	O
in	O
secondary	O
hyperalgesia	B-Disease
is	O
decreased	O
when	O
attention	O
is	O
distracted	O
away	O
from	O
the	O
painful	O
pinprick	O
stimulus	O
with	O
a	O
visual	O
task	O
.	O

However	O
,	O
when	O
the	O
patient	O
was	O
questioned	O
about	O
use	O
of	O
herbal	O
products	O
and	O
supplements	O
,	O
the	O
use	O
of	O
creatine	B-Chemical
monohydrate	O
was	O
revealed	O
.	O

Therefore	O
,	O
conversion	O
should	O
be	O
considered	O
for	O
patients	O
who	O
have	O
not	O
developed	O
advanced	O
CAN	B-Disease
and	O
proteinuria	B-Disease
.	O

Apomorphine	B-Chemical
,	O
a	O
nonselective	O
dopamine	B-Chemical
agonist	I-Chemical
,	O
was	O
selected	O
due	O
to	O
its	O
biphasic	O
behavioral	O
effects	O
,	O
its	O
ability	O
to	O
induce	O
hypothermia	B-Disease
,	O
and	O
to	O
produce	O
distinct	O
changes	O
to	O
dopamine	B-Chemical
turnover	O
in	O
the	O
rodent	O
brain	O
.	O

OBJECTIVES	O
:	O
To	O
estimate	O
the	O
frequency	O
and	O
severity	O
of	O
valvular	B-Disease
heart	I-Disease
abnormality	I-Disease
and	O
its	O
possible	O
reversibility	O
after	O
drug	O
withdrawal	O
in	O
a	O
case	O
-	O
control	O
study	O
.	O

Compared	O
with	O
placebo	O
,	O
modafinil	B-Chemical
decreased	O
nighttime	O
sleep	O
latency	O
and	O
increased	O
slow	O
-	O
wave	O
sleep	O
time	O
in	O
cocaine	B-Chemical
-	O
dependent	O
participants	O
.	O

We	O
report	O
a	O
favorable	O
response	O
to	O
treatment	O
with	O
citalopram	B-Chemical
by	O
a	O
15	O
-	O
year	O
-	O
old	O
boy	O
with	O
major	B-Disease
depression	I-Disease
who	O
exhibited	O
palpebral	B-Disease
twitching	I-Disease
during	O
his	O
first	O
2	O
weeks	O
of	O
treatment	O
.	O

Twenty	O
common	O
migraine	B-Disease
patients	O
received	O
a	O
one	O
sided	O
frontotemporal	O
application	O
of	O
nitroglycerin	B-Chemical
(	O
10	O
patients	O
)	O
or	O
placebo	O
ointment	O
(	O
10	O
patients	O
)	O
in	O
a	O
double	O
blind	O
study	O
.	O

The	O
possible	O
beneficial	O
effect	O
of	O
ribavirin	B-Chemical
during	O
the	O
initial	O
days	O
of	O
AHF	B-Disease
is	O
discussed	O
.	O

The	O
association	O
remained	O
after	O
additional	O
adjustment	O
for	O
diabetes	B-Disease
,	O
cholesterol	B-Chemical
level	O
,	O
systolic	O
blood	O
pressure	O
,	O
or	O
alcohol	B-Chemical
use	O
.	O

Grade	O
3	O
-	O
4	O
adverse	O
effects	O
included	O
myelosuppression	B-Disease
,	O
fatigue	B-Disease
,	O
somnolence	B-Disease
/	O
depressed	B-Disease
mood	I-Disease
,	O
neuropathy	B-Disease
and	O
dyspnea	B-Disease
.	O

Oral	O
administration	O
of	O
CBZ	B-Chemical
as	O
an	O
aqueous	O
suspension	O
every	O
8	O
h	O
at	O
a	O
dose	O
of	O
250	O
mg	O
/	O
kg	O
was	O
continuously	O
protective	O
against	O
HFDE	B-Chemical
-	O
induced	O
seizures	B-Disease
and	O
was	O
minimally	O
toxic	O
as	O
measured	O
by	O
weight	B-Disease
gain	I-Disease
over	O
8	O
weeks	O
of	O
treatment	O
.	O

Pain	B-Disease
intensity	O
on	O
a	O
0	O
to	O
10	O
numerical	O
scale	O
;	O
nausea	B-Disease
and	O
vomiting	B-Disease
,	O
drowsiness	O
,	O
confusion	B-Disease
,	O
and	O
dry	B-Disease
mouth	I-Disease
,	O
using	O
a	O
scale	O
from	O
0	O
to	O
3	O
(	O
not	O
at	O
all	O
,	O
slight	O
,	O
a	O
lot	O
,	O
awful	O
)	O
;	O
Mini	O
-	O
Mental	O
State	O
Examination	O
(	O
MMSE	O
)	O
(	O
0	O
-	O
30	O
)	O
;	O
and	O
arterial	O
pressure	O
were	O
recorded	O
before	O
administration	O
of	O
drugs	O
(	O
T0	O
)	O
and	O
after	O
30	O
minutes	O
(	O
T30	O
)	O
,	O
60	O
minutes	O
(	O
T60	O
)	O
,	O
120	O
minutes	O
(	O
T120	O
)	O
,	O
and	O
180	O
minutes	O
(	O
T180	O
)	O
.	O

This	O
observation	O
demonstrates	O
that	O
prolonged	O
cholestasis	B-Disease
can	O
follow	O
troleandomycin	B-Chemical
-	O
induced	O
acute	O
hepatitis	B-Disease
.	O

The	O
gamma	B-Chemical
-	I-Chemical
aminobutyric	I-Chemical
acid	I-Chemical
-	O
transmitted	O
thalamocortical	O
circuitry	O
accounts	O
for	O
a	O
major	O
part	O
of	O
the	O
underlying	O
neurophysiology	O
of	O
the	O
absence	B-Disease
epilepsy	I-Disease
.	O

These	O
results	O
elucidated	O
ecstasy	B-Chemical
-	O
related	O
deficits	O
,	O
only	O
some	O
of	O
which	O
might	O
be	O
attributed	O
to	O
cannabis	B-Chemical
use	O
.	O

Analgesic	O
effect	O
of	O
intravenous	O
ketamine	B-Chemical
in	O
cancer	B-Disease
patients	O
on	O
morphine	B-Chemical
therapy	O
:	O
a	O
randomized	O
,	O
controlled	O
,	O
double	O
-	O
blind	O
,	O
crossover	O
,	O
double	O
-	O
dose	O
study	O
.	O

CONCLUSION	O
:	O
Our	O
results	O
suggest	O
that	O
high	O
-	O
dose	O
testosterone	B-Chemical
therapy	O
may	O
adversely	O
affect	O
atherosclerosis	B-Disease
in	O
postmenopausal	O
women	O
and	O
indicate	O
that	O
androgen	O
replacement	O
in	O
these	O
women	O
may	O
not	O
be	O
harmless	O
.	O

Recurrent	O
reversible	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
from	O
amphotericin	B-Chemical
.	O

This	O
case	O
report	O
shows	O
that	O
ciprofloxacin	B-Chemical
may	O
precipitate	O
life	O
-	O
threatening	O
thrombocytopenia	B-Disease
and	O
haemolytic	B-Disease
anaemia	I-Disease
,	O
even	O
in	O
the	O
early	O
phases	O
of	O
treatment	O
and	O
without	O
apparent	O
previous	O
exposures	O
.	O

Both	O
risperidone	B-Chemical
and	O
haloperidol	B-Chemical
produced	O
D2	O
occupancy	O
levels	O
between	O
approximately	O
60	O
and	O
90	O
%	O
at	O
standard	O
clinical	O
doses	O
.	O

Simvastatinezetimibe	B-Chemical
and	O
escitalopram	B-Chemical
(	O
which	O
she	O
was	O
taking	O
for	O
depression	B-Disease
)	O
were	O
discontinued	O
,	O
and	O
other	O
potential	O
causes	O
of	O
hepatotoxicity	B-Disease
were	O
excluded	O
.	O

Valproate	B-Chemical
-	O
induced	O
encephalopathy	B-Disease
is	O
a	O
rare	O
syndrome	O
that	O
may	O
manifest	O
in	O
otherwise	O
normal	O
epileptic	B-Disease
individuals	O
.	O

Prompt	O
restoration	O
of	O
renal	O
function	O
followed	O
drug	O
withdrawal	O
,	O
while	O
re	O
-	O
exposure	O
to	O
a	O
single	O
dose	O
of	O
indomethacin	B-Chemical
caused	O
recurrence	O
of	O
acute	O
reversible	O
oliguria	B-Disease
.	O

A	O
72	O
-	O
year	O
-	O
old	O
woman	O
was	O
admitted	O
to	O
the	O
hospital	O
with	O
"	O
flash	O
"	O
pulmonary	B-Disease
edema	I-Disease
,	O
preceded	O
by	O
chest	B-Disease
pain	I-Disease
,	O
requiring	O
intubation	O
.	O

Thus	O
,	O
while	O
whole	O
body	O
hyperthermia	B-Disease
enhances	O
Adriamycin	B-Chemical
-	O
mediated	O
antitumor	O
effect	O
,	O
normal	O
tissue	O
toxicity	B-Disease
is	O
also	O
increased	O
,	O
and	O
the	O
potential	O
therapeutic	O
gain	O
of	O
the	O
combined	O
modality	O
treatment	O
is	O
eroded	O
.	O

BACKGROUND	O
:	O
Although	O
intravitreal	O
aminoglycosides	B-Chemical
have	O
substantially	O
improved	O
visual	O
prognosis	O
in	O
endophthalmitis	B-Disease
,	O
macular	O
infarction	B-Disease
may	O
impair	O
full	O
visual	O
recovery	O
.	O

These	O
results	O
indicate	O
that	O
noradrenergic	O
neurons	O
have	O
an	O
important	O
role	O
in	O
the	O
manifestation	O
of	O
catalepsy	B-Disease
induced	O
by	O
THC	B-Chemical
,	O
whereas	O
dopaminergic	O
neurons	O
are	O
important	O
in	O
catalepsy	B-Disease
induced	O
by	O
haloperidol	B-Chemical
.	O

Multivariate	O
stepwise	O
logistic	O
regression	O
analysis	O
using	O
preoperative	O
and	O
postoperative	O
variables	O
identified	O
that	O
an	O
increase	O
of	O
serum	O
creatinine	B-Chemical
compared	O
with	O
average	O
at	O
1	O
year	O
,	O
3	O
months	O
,	O
and	O
4	O
weeks	O
postoperatively	O
were	O
independent	O
risk	O
factors	O
for	O
the	O
development	O
of	O
CRF	B-Disease
or	O
ESRD	B-Disease
with	O
odds	O
ratios	O
of	O
2	O
.	O
6	O
,	O
2	O
.	O
2	O
,	O
and	O
1	O
.	O
6	O
,	O
respectively	O
.	O

However	O
,	O
the	O
concomitant	O
occurrence	O
of	O
HBeAg	B-Chemical
negativity	O
(	O
PC	O
/	O
BCP	O
)	O
,	O
sP120T	O
,	O
and	O
LAM	B-Chemical
resistance	O
resulted	O
in	O
the	O
restoration	O
of	O
replication	O
to	O
levels	O
of	O
wild	O
-	O
type	O
HBV	O
.	O

The	O
mechanism	O
by	O
which	O
omeprazole	B-Chemical
caused	O
the	O
patient	O
'	O
s	O
hemolytic	B-Disease
anemia	I-Disease
is	O
uncertain	O
,	O
but	O
physicians	O
should	O
be	O
alerted	O
to	O
this	O
possible	O
adverse	O
effect	O
.	O

After	O
154	O
courses	O
of	O
therapy	O
,	O
the	O
median	O
dose	O
intensity	O
was	O
131	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
paclitaxel	B-Chemical
(	O
97	O
.	O
3	O
%	O
)	O
,	O
117	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
cisplatin	B-Chemical
(	O
97	O
.	O
3	O
%	O
)	O
,	O
and	O
1378	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
gemcitabine	B-Chemical
(	O
86	O
.	O
2	O
%	O
)	O
.	O

Acute	O
confusion	B-Disease
induced	O
by	O
a	O
high	O
-	O
dose	O
infusion	O
of	O
5	B-Chemical
-	I-Chemical
fluorouracil	I-Chemical
and	O
folinic	B-Chemical
acid	I-Chemical
.	O

Veno	B-Disease
-	I-Disease
occlusive	I-Disease
liver	I-Disease
disease	I-Disease
after	O
dacarbazine	B-Chemical
therapy	O
(	O
DTIC	B-Chemical
)	O
for	O
melanoma	B-Disease
.	O

In	O
a	O
placebo	O
-	O
controlled	O
,	O
single	O
-	O
blinded	O
,	O
crossover	O
study	O
,	O
we	O
assessed	O
the	O
effect	O
of	O
"	O
real	O
"	O
repetitive	O
transcranial	O
magnetic	O
stimulation	O
(	O
rTMS	O
)	O
versus	O
"	O
sham	O
"	O
rTMS	O
(	O
placebo	O
)	O
on	O
peak	O
dose	O
dyskinesias	B-Disease
in	O
patients	O
with	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
(	O
PD	B-Disease
)	O
.	O

Using	O
functional	O
magnetic	O
resonance	O
imaging	O
(	O
fMRI	O
)	O
in	O
normal	O
volunteers	O
,	O
we	O
studied	O
the	O
gabapentin	B-Chemical
-	O
induced	O
modulation	O
of	O
brain	O
activity	O
in	O
response	O
to	O
nociceptive	O
mechanical	O
stimulation	O
of	O
normal	O
skin	O
and	O
capsaicin	B-Chemical
-	O
induced	O
secondary	B-Disease
hyperalgesia	I-Disease
.	O

We	O
present	O
a	O
patient	O
with	O
pseudoacromegaly	B-Disease
that	O
resulted	O
from	O
the	O
long	O
-	O
term	O
use	O
of	O
minoxidil	B-Chemical
at	O
an	O
unusually	O
high	O
dose	O
.	O

METHODS	O
:	O
Renal	O
ACE	O
activity	O
(	O
Hip	B-Chemical
-	I-Chemical
His	I-Chemical
-	I-Chemical
Leu	I-Chemical
cleavage	O
by	O
cortical	O
homogenates	O
)	O
was	O
determined	O
by	O
renal	O
biopsy	O
in	O
27	O
adult	O
male	O
Wistar	O
rats	O
.	O

In	O
summary	O
,	O
the	O
chick	O
embryo	O
provides	O
a	O
reliable	O
and	O
simple	O
experimental	O
animal	O
model	O
of	O
coniine	B-Chemical
-	O
induced	O
arthrogryposis	B-Disease
.	O

Thirty	O
-	O
five	O
patients	O
with	O
primary	B-Disease
pulmonary	I-Disease
hypertension	I-Disease
and	O
85	O
matched	O
controls	O
were	O
recruited	O
over	O
32	O
months	O
(	O
1992	O
-	O
1994	O
)	O
in	O
Belgium	O
.	O

A	O
similar	O
bradycardic	O
effect	O
of	O
clonidine	B-Chemical
was	O
observed	O
in	O
isolated	O
spontaneously	O
beating	O
right	O
atria	O
from	O
alpha2ABC	O
-	O
knockout	O
and	O
wild	O
-	O
type	O
mice	O
.	O

We	O
then	O
used	O
hyperbaric	O
oxygen	B-Chemical
at	O
an	O
absolute	O
pressure	O
of	O
2	O
atm	O
,	O
5	O
days	O
a	O
week	O
for	O
8	O
consecutive	O
weeks	O
.	O

Valproic	B-Chemical
acid	I-Chemical
(	O
VPA	B-Chemical
)	O
is	O
a	O
broad	O
-	O
spectrum	O
antiepileptic	O
drug	O
and	O
is	O
usually	O
well	O
-	O
tolerated	O
.	O

Sexual	B-Disease
dysfunction	I-Disease
among	O
patients	O
with	O
arthritis	B-Disease
.	O

A	O
54	O
-	O
year	O
-	O
old	O
hypothyroid	B-Disease
male	O
taking	O
thyroxine	B-Chemical
and	O
simvastatin	B-Chemical
presented	O
with	O
bilateral	O
leg	O
compartment	B-Disease
syndrome	I-Disease
and	O
myonecrosis	B-Disease
.	O

These	O
results	O
suggest	O
that	O
antithrombosis	O
of	O
TET	B-Chemical
and	O
FAN	B-Chemical
in	O
mice	O
may	O
be	O
mainly	O
related	O
to	O
the	O
antiplatelet	O
aggregation	O
activities	O
.	O

The	O
incidence	O
of	O
cardiotoxicity	B-Disease
was	O
not	O
higher	O
in	O
patients	O
with	O
signs	O
of	O
cardiovascular	B-Disease
disease	I-Disease
than	O
in	O
those	O
without	O
in	O
the	O
pre	O
-	O
treatment	O
evaluation	O
.	O

CONCLUSIONS	O
:	O
A	O
comparison	O
of	O
frequency	O
of	O
adverse	O
reactions	O
to	O
indocyanine	B-Chemical
green	I-Chemical
with	O
the	O
previously	O
reported	O
frequency	O
of	O
such	O
reactions	O
to	O
fluorescein	B-Chemical
sodium	I-Chemical
indicated	O
that	O
indocyanine	B-Chemical
green	I-Chemical
is	O
a	O
safe	O
as	O
fluorescein	B-Chemical
for	O
use	O
in	O
angiography	O
.	O

The	O
maximal	O
NGF	O
contents	O
obtained	O
by	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
were	O
17	O
.	O
6	O
-	O
fold	O
of	O
the	O
control	O
value	O
.	O

Reserpine	B-Chemical
injection	O
(	O
one	O
dose	O
of	O
1	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
every	O
other	O
day	O
for	O
3	O
days	O
caused	O
a	O
significant	O
increase	O
in	O
vacuous	O
chewing	O
,	O
tongue	O
protrusion	O
and	O
duration	O
of	O
facial	O
twitching	O
,	O
compared	O
to	O
the	O
control	O
.	O

Animals	O
were	O
administered	O
nicotine	B-Chemical
,	O
carbachol	B-Chemical
,	O
or	O
neostigmine	B-Chemical
via	O
timed	O
tail	O
vein	O
infusion	O
,	O
and	O
the	O
latencies	O
to	O
onset	O
of	O
tremor	B-Disease
and	O
clonus	O
were	O
recorded	O
and	O
converted	O
to	O
threshold	O
dose	O
.	O

The	O
therapeutic	O
potential	O
of	O
the	O
anticocaine	O
antibody	O
GNC92H2	B-Chemical
was	O
examined	O
using	O
a	O
model	O
of	O
cocaine	B-Disease
overdose	I-Disease
.	O

The	O
occurrence	O
of	O
infarcts	B-Disease
were	O
confirmed	O
by	O
histological	O
methods	O
.	O

Psychologists	O
need	O
to	O
inquire	O
about	O
consumption	O
of	O
quinine	B-Chemical
-	O
containing	O
beverages	O
as	O
part	O
of	O
an	O
evaluation	O
process	O
.	O

In	O
contrast	O
to	O
the	O
protection	O
provided	O
by	O
the	O
putative	O
antagonists	O
,	O
the	O
well	O
-	O
characterized	O
sigma	O
receptor	O
agonist	O
di	B-Chemical
-	I-Chemical
o	I-Chemical
-	I-Chemical
tolylguanidine	I-Chemical
(	O
DTG	B-Chemical
)	O
and	O
the	O
novel	O
sigma	O
receptor	O
agonist	O
BD1031	B-Chemical
(	O
3R	B-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
[	I-Chemical
2	I-Chemical
-	I-Chemical
(	I-Chemical
3	I-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
dichlorophenyl	I-Chemical
)	I-Chemical
ethyl	I-Chemical
]	I-Chemical
-	I-Chemical
1	I-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
diazabicyclo	I-Chemical
[	I-Chemical
4	I-Chemical
.	I-Chemical
3	I-Chemical
.	I-Chemical
0	I-Chemical
]	I-Chemical
nonane	I-Chemical
)	O
each	O
worsened	O
the	O
behavioral	O
toxicity	B-Disease
of	O
cocaine	B-Chemical
.	O

The	O
correlation	O
between	O
neuropathic	B-Disease
damage	I-Disease
and	O
inhibition	O
of	O
neurotoxic	B-Disease
esterase	O
or	O
neuropathy	B-Disease
target	O
enzyme	O
(	O
NTE	O
)	O
was	O
examined	O
in	O
rats	O
acutely	O
exposed	O
to	O
Mipafox	B-Chemical
(	O
N	B-Chemical
,	I-Chemical
N	I-Chemical
'	I-Chemical
-	I-Chemical
diisopropylphosphorodiamidofluoridate	I-Chemical
)	O
,	O
a	O
neurotoxic	B-Disease
organophosphate	B-Chemical
.	O

With	O
last	O
observations	O
carried	O
forward	O
(	O
LOCF	O
)	O
,	O
mean	O
Positive	O
and	O
Negative	O
Syndrome	O
Scale	O
total	O
score	O
reductions	O
from	O
baseline	O
to	O
endpoint	O
were	O
significantly	O
greater	O
with	O
asenapine	B-Chemical
at	O
5	O
mg	O
BID	O
(	O
-	O
16	O
.	O
2	O
)	O
and	O
haloperidol	B-Chemical
(	O
-	O
15	O
.	O
4	O
)	O
than	O
placebo	O
(	O
-	O
10	O
.	O
7	O
;	O
both	O
P	O
<	O
0	O
.	O
05	O
)	O
;	O
using	O
mixed	O
model	O
for	O
repeated	O
measures	O
(	O
MMRM	O
)	O
,	O
changes	O
at	O
day	O
42	O
were	O
significantly	O
greater	O
with	O
asenapine	B-Chemical
at	O
5	O
and	O
10	O
mg	O
BID	O
(	O
-	O
21	O
.	O
3	O
and	O
-	O
19	O
.	O
4	O
,	O
respectively	O
)	O
and	O
haloperidol	B-Chemical
(	O
-	O
20	O
.	O
0	O
)	O
than	O
placebo	O
(	O
-	O
14	O
.	O
6	O
;	O
all	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

One	O
patient	O
was	O
prematurely	O
discontinued	O
from	O
the	O
study	O
for	O
severe	O
headache	B-Disease
and	O
abdominal	B-Disease
pain	I-Disease
.	O

Control	O
chicks	O
were	O
in	O
motion	O
an	O
average	O
of	O
33	O
.	O
67	O
%	O
of	O
the	O
time	O
,	O
while	O
coniine	B-Chemical
-	O
treated	O
chicks	O
were	O
only	O
moving	O
8	O
.	O
95	O
%	O
of	O
a	O
5	O
-	O
min	O
interval	O
,	O
and	O
no	O
movement	O
was	O
observed	O
for	O
nicotine	B-Chemical
sulfate	O
treated	O
chicks	O
.	O

Nephrolithiasis	B-Disease
is	O
a	O
complication	O
of	O
acetazolamide	B-Chemical
but	O
does	O
not	O
preclude	O
its	O
use	O
.	O

Blood	O
pressure	O
response	O
to	O
chronic	O
low	O
-	O
dose	O
intrarenal	O
noradrenaline	B-Chemical
infusion	O
in	O
conscious	O
rats	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
if	O
prenatal	O
dexamethasone	B-Chemical
programmed	O
a	O
progressive	O
increase	B-Disease
in	I-Disease
blood	I-Disease
pressure	I-Disease
and	O
renal	B-Disease
injury	I-Disease
in	O
rats	O
.	O

These	O
episodes	O
reversed	O
after	O
the	O
administration	O
of	O
diazepam	B-Chemical
1	O
mg	O
intravenously	O
.	O

Hemolysis	B-Disease
of	O
human	O
erythrocytes	O
induced	O
by	O
tamoxifen	B-Chemical
is	O
related	O
to	O
disruption	O
of	O
membrane	O
structure	O
.	O

Findings	O
suggest	O
a	O
potential	O
for	O
H	O
(	O
3	O
)	O
-	O
receptor	O
antagonists	O
in	O
improving	O
the	O
refractory	O
cases	O
of	O
schizophrenia	B-Disease
.	O

However	O
,	O
the	O
threshold	O
(	O
61	O
.	O
6	O
+	O
/	O
-	O
8	O
.	O
7	O
mg	O
.	O
l	O
(	O
-	O
1	O
)	O
)	O
during	O
1	O
.	O
6	O
%	O
sevoflurane	B-Chemical
was	O
not	O
significant	O
from	O
that	O
during	O
0	O
.	O
8	O
%	O
sevoflurane	B-Chemical
,	O
indicating	O
a	O
celling	O
effect	O
.	O

Sequential	O
observations	O
of	O
exencephaly	B-Disease
and	O
subsequent	O
morphological	O
changes	O
by	O
mouse	O
exo	O
utero	O
development	O
system	O
:	O
analysis	O
of	O
the	O
mechanism	O
of	O
transformation	O
from	O
exencephaly	B-Disease
to	O
anencephaly	B-Disease
.	O

Other	O
antibacterial	O
agents	O
that	O
showed	O
associations	O
included	O
erythromycins	B-Chemical
(	O
2	O
defects	O
)	O
,	O
penicillins	B-Chemical
(	O
1	O
defect	O
)	O
,	O
cephalosporins	B-Chemical
(	O
1	O
defect	O
)	O
,	O
and	O
quinolones	B-Chemical
(	O
1	O
defect	O
)	O
.	O

In	O
the	O
antinociceptive	O
and	O
antiamnesic	O
dose	O
range	O
,	O
(	O
+	O
/	O
-	O
)	O
-	O
PG	B-Chemical
-	I-Chemical
9	I-Chemical
did	O
not	O
impair	O
mouse	O
performance	O
evaluated	O
by	O
the	O
rota	O
-	O
rod	O
test	O
and	O
Animex	O
apparatus	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
effects	O
of	O
maternal	O
smoking	B-Chemical
on	O
transient	O
evoked	O
otoacoustic	O
emissions	O
(	O
TEOAEs	O
)	O
of	O
healthy	O
neonates	O
.	O

Using	O
as	O
the	O
reference	O
group	O
women	O
who	O
were	O
not	O
using	O
oral	O
contraception	O
,	O
had	O
no	O
recent	O
pregnancy	O
or	O
menopausal	O
symptoms	O
,	O
the	O
case	O
-	O
control	O
analysis	O
gave	O
an	O
adjusted	O
odds	O
ratio	O
(	O
OR	O
(	O
adj	O
)	O
)	O
of	O
7	O
.	O
44	O
(	O
95	O
%	O
CI	O
3	O
.	O
67	O
-	O
15	O
.	O
08	O
)	O
for	O
CPA	B-Chemical
/	O
EE	B-Chemical
use	O
compared	O
with	O
an	O
OR	O
(	O
adj	O
)	O
of	O
2	O
.	O
58	O
(	O
95	O
%	O
CI	O
1	O
.	O
60	O
-	O
4	O
.	O
18	O
)	O
for	O
use	O
of	O
conventional	O
COCs	O
.	O

Serotonergic	B-Chemical
antidepressants	I-Chemical
and	O
urinary	B-Disease
incontinence	I-Disease
.	O

Noxious	O
chemical	O
stimulation	O
of	O
rat	O
facial	O
mucosa	O
increases	O
intracranial	O
blood	O
flow	O
through	O
a	O
trigemino	O
-	O
parasympathetic	O
reflex	O
-	O
-	O
an	O
experimental	O
model	O
for	O
vascular	B-Disease
dysfunctions	I-Disease
in	O
cluster	B-Disease
headache	I-Disease
.	O

These	O
findings	O
indicate	O
that	O
in	O
spontaneously	O
hypertensive	B-Disease
rats	O
the	O
effects	O
of	O
central	O
alpha	O
-	O
adrenoceptor	O
stimulation	O
involve	O
activation	O
of	O
opiate	O
receptors	O
.	O

In	O
conclusion	O
,	O
reductions	O
in	O
creatinine	B-Chemical
clearance	O
and	O
renal	O
amphotericin	B-Chemical
B	I-Chemical
accumulation	O
after	O
chronic	O
amphotericin	B-Chemical
B	I-Chemical
administration	O
were	O
enhanced	O
by	O
salt	O
depletion	O
and	O
attenuated	O
by	O
sodium	B-Chemical
loading	O
in	O
rats	O
.	O

Recurrence	O
of	O
hepatitis	B-Disease
attack	O
might	O
have	O
been	O
avoided	O
if	O
the	O
initial	O
incident	O
had	O
been	O
communicated	O
to	O
the	O
attending	O
physician	O
who	O
prescribed	O
telithromycin	B-Chemical
the	O
second	O
time	O
.	O

To	O
determine	O
if	O
the	O
addition	O
of	O
a	O
buffering	O
solution	O
to	O
adjust	O
the	O
pH	O
of	O
lidocaine	B-Chemical
into	O
the	O
physiologic	O
range	O
would	O
reduce	O
pain	B-Disease
during	O
injection	O
,	O
we	O
performed	O
a	O
blinded	O
randomized	O
study	O
in	O
patients	O
undergoing	O
cardiac	O
catheterization	O
.	O

Warfarin	B-Chemical
is	O
the	O
most	O
widely	O
used	O
oral	O
anticoagulant	O
and	O
is	O
indicated	O
for	O
many	O
clinical	O
conditions	O
.	O

